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The extent of interaction between calcium channel antagonists and grapefruit juice varies 
widely among drugs.  Coadministration of calcium channel antagonists with grapefruit 
juice can elevate the bioavailability of drugs and alter pharmacokinetic parameters of the 
drug.  A calcium channel antagonist with lower bioavailability is likely to be more affect-
ed by grapefruit juice.  The area under the concentration-time curve and peak serum con-
centrations of azelnidipine, efonidipine, felodipine, manidipine, nicardipine, nifedipine, 
nisoldipine, nitrendipine and verapamil are influenced by grapefruit juice.  Conversely, 
pharmacokinetic parameters of amlodipine and diltiazem are not affected by grapefruit 
juice.  The action of grapefruit juice is rapid, and a single exposure to one glass of juice 
can usually produce a significant interaction.  Furanocoumarins primarily contribute to 
grapefruit juice-drug interactions in humans.  Cytochrome P4503A4 and P-glycoprotein 
may act in tandem as a barrier to oral delivery of drugs.  The main mechanism for en-
hanced bioavailability of drugs by grapefruit juice is, presumably, the inhibition of cyto-
chrome P4503A4 in the small intestine and only to a minor extent affected by P-glycopro-
tein function.  There are dose-dependent and time-dependent effects of grapefruit juice 
on cytochrome P4503A4.  Since biosynthesis of new cytochrome P4503A4 is necessary, the 
duration of the interaction is consistent with the pharmacological mechanism of interac-
tion; inhibition of enzyme activities by grapefruit juice persists for approximately 3 days.
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Patients are frequently treated with multiple medi-
cines concurrently in order to treat one or more 
medical problems with drug therapy.  Although 
concomitant intake of 2 or more drugs can alter 
their efficacy, available information regarding 
drug activity pertains to each drug separately. 
Hence, an interaction is said to take place when 
the effects of one drug are modified by the pres-
ence of another drug, food or environmental 
chemical agent.  For approximately 2 decades, a 
major focal point in the area of food-drug inter-
actions has been regarding interactions of grape-
fruit with several drugs, such as lipid-lowering 
drugs and calcium channel antagonists (Bailey 
and Dresser, 2004).  In an initial report regard-
ing grapefruit juice (GFJ) and drug interactions, 
investigators observed an interaction between 
felodipine and GFJ in a study of felodipine and 
ethanol in which GFJ was used to mask the taste 
of ethanol (Bailey et al., 1989).  Subsequent stud-
ies confirmed that GFJ significantly increased the 
oral bioavailability of felodipine (Bailey et al., 
1991; Edgar et al., 1992).
 Drug concentration at the cellular site of 
action represents the net result of absorption, 
distribution and elimination, which is often deter-
mined by mechanisms involving the metabolism 
or transport of a drug (Bailey and Dresser, 2004). 
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Many endogenous compounds, in addition to 
drugs, are metabolized in the body by cytochrome 
P450 (CYP) enzyme systems through oxidative 
biotransformation.  The isozyme CYP3A4 is the 
predominant form in the human small intestine 
(Kolars et al., 1992), while a very limited number 
of other CYP isoforms are expressed in the small 
intestine (Zhang et al., 1999).  The location of 
CYP3A4 in the small bowel and liver permits an 
effect on both presystemic and systemic drug dis-
position (Dresser et al., 2000b).  In most cases, the 
extent of drug interaction varies markedly among 
individuals; this is likely to be dependent on in-
terindividual differences in CYP3A4 tissue con-
tent, pre-existing medical conditions and possibly 
age (Dresser et al., 2000b).  Clinically important 
CYP3A4 inhibitors include itraconazole, ketokon-
azole, clarithromycin, erythromycin, nefazodone, 
ritonavir and GFJ (Dresser et al., 2000b).
 There are more than 10 oral calcium channel 
antagonists available in Japan.  Calcium channel 
antagonists are used widely in clinical treatment 
of hypertension and angina pectoris.  Calcium 
channel antagonists are well absorbed from the 
intestine, and the first-pass metabolism mediated 
by CYP3A4 in the liver and intestine is a major 
determinant of bioavailability.  The coadministra-
tion of these drugs with GFJ can markedly elevate 
bioavailability of drugs and can alter pharmacoki-
netic parameters of the drug.  Although the extent 
of interaction between calcium channel antagonists 
and GFJ varies widely among individuals, in the 
short term this interaction is reproducible within 
individuals.  A drug with lower bioavailability is 
likely to be more impacted by GFJ (Fuhr, 1998; 
Ohnishi et al., 2006).  A calcium channel antago-
nist with lower bioavailability or higher plasma 
protein binding ratio is likely to exhibit a more 
potent interaction with GFJ (Ohnishi et al., 2006). 
Ohnishi et al. (2006) considered that this informa-
tion should be useful to avoid adverse drug inter-
actions and to predict the extent of interaction in 
a clinical situation and during drug development. 
Amlodipine and nifedipine have better inherent 
oral bioavailability and hence are less affected by 
GFJ (Bailey et al., 1991; Josefsson et al., 1996). 
Although metabolized in vivo by CYP3A4, the 
nondihydropyridine calcium channel antagonists 
diltiazem and verapamil were not affected by GFJ 
in small clinical studies (Zaidenstein et al., 1998). 
Amounts of GFJ in the range normally consumed 
(up to 3 glasses per day) seem to have intestinal 
activity only (Garvan and James, 2000).
 This short review reveals the effect of GFJ 
on pharmacokinetic parameters, such as the peak 
plasma (or serum) concentration (Cmax) and the 
area under the concentration-time curve (AUC), 
as well as pharmacodynamic parameters, such 
as blood pressure and heart rate, of oral calcium 
channel antagonists in humans.
 
Mechanism of interaction
 
A food-drug interaction may be defined mainly 
as the alteration of absorption and/or metabolism 
of a drug by a food component.  The underlying 
mechanisms can be classified into 2 broad cat-
egories.  The first is pharmacokinetics, including 
alterations in absorption, distribution, metabolism 
and excretion; the second is pharmacodynamics, 
describing alterations in the drug concentration-
effect relationship (Dresser et al., 2000b).  The ac-
tion of GFJ is rapid and a single exposure to one 
glass of juice can usually produce a significant 
interaction (Lundahl et al., 1998).  There are dose-
dependent (Lilja et al., 2000) and time-dependent 
(Lundahl et al., 1995) effects of GFJ on CYP3A4. 
Uesawa and Mohri (2008) reported that lipophi-
licity is an important factor in the strength of 
pharmacokinetics of dihydropyridines with GFJ 
intake based on the result that logP values indi-
cate significant positive correlations with interac-
tion strength.
 CYP enzymes are predominantly expressed 
in the liver, although they are also present in the 
extra-hepatic tissues such as the intestinal mucosa. 
CYP3A comprises on average 30% of all CYP in 
the liver and as much as 70% in small intestine 
epithelial cells (Kane and Lipsky, 2000).  CY-
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P3A4 is the most abundantly expressed isoform 
and is highly expressed in the intestinal mucosa. 
Although the liver was assumed to be the major 
site of grapefruit-drug interactions initially, it is 
indicated that the interaction may take place dur-
ing the gastrointestinal absorption phase, based 
on the result that the interaction only occurs when 
drugs are administered orally, not intravenously 
(Lundahl et al., 1997).  GFJ can inhibit the activ-
ity of intestinal CYP3A4, leading to an interac-
tion with drugs during their first passage from the 
intestinal lumen into systemic circulation (Lown 
et al., 1997).  Dahan and Altman (2004) reported 
that only intestinal CYP3A4 is inhibited by GFJ, 
while liver resident CYP3A4 enzymes are not af-
fected.  This result is supported by the finding that 
interaction with GFJ markedly elevated the AUC, 
while no significant change has been observed in 
elimination half-life or systemic clearance (Bailey 
et al., 1991).  The effect of GFJ on felodipine has 
been shown to exist at approximately 30% of its 
maximum even when the drug was administered 
24 h following juice intake (Lundahl et al., 1995). 
Since biosynthesis of a new CYP3A4 is necessary, 
the duration of the interaction is consistent with 
the pharmacological mechanism of interaction.
 P-glycoprotein, one of the multiple drug 
resistance transporters, reduces the fraction of 
drug absorbed by carrying the drug from the en-
terocyte back to the intestinal lumen (Gottesman 
et al., 1996).  GFJ modifies P-glycoprotein trans-
porter activity.  Although there was little data sug-
gesting activation of P-glycoprotein efflux by GFJ 
(Phang et al., 1993; Soldner et al., 1999), most in-
vestigators observed inhibition of transporter ac-
tivity (Takanaga et al., 1998; Eagling et al., 1999; 
Wang et al., 2001; Tian et al., 2002).  Inhibition 
of P-glycoprotein is a possible mechanism that 
increases oral drug bioavailability by reducing in-
testinal and/or hepatic efflux transport (Bailey and 
Dresser, 2004).  Kane and Lipsky (2000) reported 
CYP3A4 and P-glycoprotein may act in tandem 
as a barrier to the oral delivery of many drugs.
 Goosen et al. (2004) reported that bergamot-
tin enhanced the oral bioavailability of felodipine 
and may cause a clinically relevant drug inter-
action in susceptible individuals.  Furthermore, 
GFJ-drug interactions likely also involve other 
furanocoumarins, possibly acting in combination 
by additive or synergistic mechanisms.  Kakar 
et al. (2004) reported that 6',7'-dihydrobergamot-
tin is an important contributor to the GFJ effect. 
Paine et al. (2006) reported that furanocoumarins 
(bergamottin, 6',7'-dihydrobergamottin and fura-
nocoumarin dimers) are the active ingredients in 
GFJ responsible for enhancing systemic exposure 
of felodipine.
 Presumably, the main mechanism for en-
hanced bioavailability of drugs by GFJ is the inhi-
bition of CYP3A4 in the small intestine (Edwards 
et al., 1996; Lown et al., 1997), resulting in a sig-
nificant reduction of presystemic metabolism, and 
only to a minor extent influenced by P-glycoprotein 
function (Dahan and Altman, 2004).
 
Drug interactions in 
each calcium channel antagonist (Table 1)
 
 
Dihydropyridines
 
Amlodipine
Amlodipine has a different pharmacokinetic 
profile from other dihydropyridines (Abernethy, 
1989; Meredith and Elliott, 1992).  Specifically, 
amlodipine has a lower hepatic extraction ratio, 
hence its higher oral bioavailability, and a later 
time to peak plasma concentration in addition to a 
longer plasma elimination half-life compared with 
other dihydropyridines.  When amlodipine (5 mg) 
was coadministered with a glass of GFJ (250 mL), 
Cmax was 115% and AUC (0–72 h) was 116% 
compared with water administration in healthy 
volunteers.  There were no significant differences 
in blood pressure and heart rate between the 2 
treatments (Josefsson et al., 1996).  The AUC ratio 
of GFJ (250 mL once daily for 9 days) to water 
for amlodipine (10 mg) was 107.8% and the Cmax 
ratio was 107.1%.  There were no statistically sig-
nificant treatment effects on blood pressure during 
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amlodipine administration.  Vincent et al. (2000) 
concluded that once daily GFJ administration 
with usual oral doses of amlodipine is unlikely to 
alter the profile of response in clinical practice.
Azelnidipine
Azelnidipine is an L-type calcium channel an-
tagonist, which is categorized as third generation 
type-B (Toyo-oka, 2006).  The remarkable char-
acteristics of azelnidipine that differentiate it from 
other analogues are i) the lower possibility to 
cause sinus bradycardia in patients and ii) longer-
lasting pharmacological effects even with a once 
daily dose of 8 to 16 mg (Kuramoto et al., 2003). 
Concomitant administration of azelnidipine with 
GFJ increased the Cmax of azelnidipine by 2.5-
fold and the AUC by 3.3-fold compared with 
water.  No serious adverse events were observed 
except one subject described mild symptoms of 
drug-related headache and flushing accompanied 
with orthostatic hypotension at 4 h after adminis-
tration of GFJ (Hirashima et al., 2006).
Table 1.  Pharmacokinetic interactions between calcium channel antagonists and GFJ
        Calcium Dose GFJ AUC Cmax Bio- Reference
        channel (mg) (mL) (value relative  (value relative availability
      antagonist   to control) to control) (%)
Dihydropyridine
     Amlodipine 5 250 1.14 1.15 64 Josefsson et al., 1996
 10 240 1.08 1.07  Vincent et al., 2000
     Azelnidipine 8 250 3.28 2.49    NA Hirashima et al., 2006
     Efonidipine 40 250 1.67  1.55     NA Yajima et al., 2003
     Felodipine 5 200, 250 2.51–2.88 2.23–4.00 15 Bailey et al., 1991
 10 200, 240 1.72–2.16 2.38–3.25  Edgar et al., 1992
      Lown et al., 1997
      Lundahl et al., 1997, 1998
      Dresser et al., 2000a
     Manidipine 40 250      NA Uno et al., 2006
 (S)-manidipine  2.37 2.40 
 (R)-manidipine  3.03 3.39
     Nicardipine 40 300   15–45 Guengerich et al., 1991
 (+)-nicardipine  1.43  —  Uno et al., 2000
 (–)-nicardipine  1.84  —
     Nifedipine 10 200 1.47–1.58 1.04–1.16 43 Waller et al., 1984
 20 200, 250 1.09–2.02 1.27–2.00  Rashid et al., 1993, 1995
      Sigusch et al., 1994
      Azuma et al., 1998
     Nisoldipine 10 250 4.55 3.06 3.7–8.4 Friedel and Sorkin, 1988 
 20 250 1.76 3.50   Bailey et al., 1993
      Azuma et al., 1998
     Nitrendipine 20 150   5–30 Krol et al., 1987
 (S)-nitrendipine  2.22 2.01  Mikus et al., 1987
 (R)-nitrendipine  2.36  2.15   Soons et al., 1989, 1991
Non-dihydropyridine
     Diltiazem 120 200, 250 1.10–1.18 1.02–1.14 40–50 Buckley et al., 1990
      Sigusch et al., 1994
      Christensen et al., 2002
     Verapamil 120 250   20 McTavish and Sorkin, 1989
 (S)-verapamil  1.36–1.47 1.58–1.70  Ho et al., 2000
 (R)-verapamil  1.28–1.41 1.40–1.54  Fuhr et al., 2002
AUC, area under the concentration-time curve; Cmax, peak plasma (or serum) concentration; GFJ, grapefruit juice; 
NA, not available. 
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Efonidipine
Efonidipine has longer-lasting pharmacological 
effects.  Cmax and AUC of efonidipine (40 mg) in 
20 male volunteers coadministered with GFJ were 
155% and 167% of those taking efonidipine with-
out GFJ, respectively.  There were no significant 
differences in the incidence of adverse events be-
tween administrations with or without GFJ.  The 
transitional patterns of blood pressure and heart 
rate were very similar between those with GFJ 
and those without (Yajima et al., 2003).
Felodipine
Bioavailability of felodipine is low (15%) at a dose 
of 5 mg per person (Edgar et al., 1992).  There are 
many reports about interaction between felodipine 
and GFJ.  Six men with borderline hypertension 
received felodipine (5 mg) with 250 mL of wa-
ter or with 250 mL of GFJ.  GFJ increased AUC 
and bioavailability by 284% (range 164–469) and 
134% (range 108–169), respectively.  Diastolic 
blood pressure was reduced more (–20 versus –11) 
and heart rate increased more (22 versus 9) with 
GFJ than with water (Bailey et al., 1991).  When 
felodipine (5 mg) was administered with either 
200 mL of water or GFJ in 9 healthy male volun-
teers, GFJ increased Cmax of felodipine from 6 to 
16 nmol/L, and AUC from 23 to 65 nmol/L com-
pared to water.  Blood pressure measured in the 
morning 3 h after dosing with GFJ was 9% lower 
compared to control (Edgar et al., 1992).  In a 
randomized cross-over study in 9 volunteers, GFJ 
administered 1, 4, 10 or 24 h before and simulta-
neously with drug administration resulted in a 32–
99% increase in Cmax of felodipine (10 mg), rela-
tive to concomitant water and felodipine intake. 
The effect on AUC was also significant when GFJ 
was ingested up to 10 h before administration of 
the drug.  Interaction decreased with an increase 
in time between GFJ and drug intake (Lundahl et 
al., 1995).  Twelve healthy volunteers received 150 
mL water or 150 mL of GFJ 15 min prior to oral 
felodipine (10 mg) administration.  GFJ increased 
AUC, Cmax and the absolute bioavailability by 
72%, 173% and 112%, respectively.  GFJ intake 
immediately before felodipine administration re-
sulted in more pronounced hemodynamic effects 
of the drug in diastolic blood pressure and heart 
rate (Lundahl et al., 1997).  Twelve elderly sub-
jects received oral felodipine (5 mg) with 250 mL 
of GFJ or water; AUC and Cmax of felodipine 
were 2.9- and 4.0-fold greater, respectively, with 
GFJ.  Systolic and diastolic blood pressures were 
lower with GFJ in the single-dose study (Dresser 
et al., 2000a).
Manidipine
Manidipine has potent and long-lasting activities 
(Cheer and McClelln, 2001).  The pharmacologi-
cal effects of manidipine enantiomers are known 
to be different and the pharmacological potency 
of (S)-type has been found to be greater than that 
of (R)-type (Kajino et al., 1989).  GFJ significantly 
increased Cmax and AUC of (S)-manidipine by 
2.4- and 2.3-fold, respectively; and Cmax and 
AUC of (R)-manidipine increased by 3.4- and 
3.0-fold, respectively.  There were significant dif-
ferences in GFJ-mediated percentage increases in 
Cmax and AUC of (S)-manidipine compared with 
those of (R)-manidipine.  There were no signifi-
cant differences in pharmacodynamic variables, 
arterial blood pressure and heart rate, between the 
2 enantiomers (Uno et al., 2006).
Nicardipine
Containing a chiral center like other dihydro-
pyridines, nicardipine possesses potent activities 
(Freedman and Waters, 1987).  Bioavailability 
of nicardipine is low (15–45%) at a dose of 10 to 
40 mg per person, due to extensive presystemic 
elimination (Guengerich et al., 1991).  When ni-
cardipine (40 mg) was administered 30 min after 
ingestion of 300 mL of water or concentrated 
GFJ in 6 normal healthy male volunteers, GFJ 
increased the mean oral bioavailability of (+)- and 
(–)-nicardipine, 48.6% and 105.6% respectively, 
compared with water intake.  AUC was 143% 
and 191% compared with water for (+) and (–) 
enantiomers, respectively.  Compared against wa-
ter, GFJ did not alter the mean pharmacodynamic 
variables assessed in the study except for heart 
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rates at 1 h and 2 h, following the oral dosing of 
racemic nicardipine (Uno et al., 2000).  How-
ever all of the mean kinetic parameters of both 
enantiomers following intravenous dosing of ra-
cemic nicardipine did not differ between the GFJ 
and water intake.  Uno et al. (2000) concluded 
that the gut is the major presystemic disposal site 
of racemic nicardipine in humans.
Nifedipine
Nifedipine is a lipid-soluble drug which is ab-
sorbed completely from the gut but has a low 
bioavailability due to extensive presystemic me-
tabolism (Foster et al., 1983; Waller et al., 1984). 
Bioavailability of nifedipine was reported as 43% 
(Waller et al., 1984).  Eight healthy volunteers re-
ceived nifedipine (10 mg) with 200 mL of water 
or double strength GFJ; the AUC for nifedipine 
with GFJ (320 ng•h/mL) increased significantly 
compared with the AUC when nifedipine was 
given alone (218 ng•h /mL).  The Cmax was un-
changed by administration of GFJ (Rashid et al., 
1993).  In another study, 8 healthy volunteers re-
ceived nifedipine (10 mg) with 200 mL of water 
or double strength GFJ both 2 h before and at the 
time of dosing; the administration of GFJ resulted 
in a significantly increased AUC (191 versus 301 
ng•h/mL) and bioavailability (0.63 versus 0.86). 
The elimination half-life was unchanged by ad-
ministration of GFJ (Rashid et al., 1995).  Ten 
healthy volunteers received 20 mg nifedipine 
(control-released tablet) with 200 mL of GFJ or 
water; the AUC and Cmax of GFJ phase were on 
average 103% (range 48–265) and 94% (range 
–23 to 259) higher than those in the control phase 
(Sigusch et al., 1994).  Eight healthy volunteers re-
ceived oral nifedipine (20 mg), and no particular 
differences were shown in the plasma concentra-
tions of nifedipine with GFJ (250 mL) or water 
ingestion.  Nifedipine was also well tolerated in 4 
dosing schedules (Azuma et al., 1998).
Nisoldipine
Twelve healthy men received nisoldipine (20 mg) 
with either 250 mL water or 250 mL GFJ; GFJ 
increased plasma nisoldipine concentrations be-
tween 90 min to 6 h compared with water.  Ni-
soldipine Cmax was 406% (range 107–836), and 
AUC was 198% (range 81–682) compared with 
water.  Minor effects on supine blood pressure 
and heart rate were observed, probably because 
subjects were normotensive (Bailey et al., 1993). 
Eight healthy volunteers received oral nisoldipine 
(10 mg), and significant increases in Cmax and 
AUC were observed when the drug was adminis-
tered with GFJ and 1 h after subjects ingested GFJ 
compared with drug administration with water 
only.  Nisoldipine was also well tolerated in 4 dos-
ing schedules (Azuma et al., 1998).  In a clinical 
study investigating the effect of various schedules 
of GFJ intake on nisoldipine pharmacokinetics 
and pharmacodynamics with 8 healthy volunteers, 
the effect of GFJ decreased time dependently and 
lasted for at least 3 days after ingestion (Takanaga 
et al., 2000).  They suggested that it is necessary 
to withhold GFJ for at least 3 days before admin-
istration of the nisoldipine to prevent GFJ-drug 
interaction.
Nitrendipine
Nitrendipine is a chiral 1,4-dihydropyridine cal-
cium channel antagonist.  The systemic bioavail-
ability of racemic nitrendipine is low and variable 
(5–30%) despite its almost complete gastrointes-
tinal absorption (Krol et al., 1987; Mikus et al., 
1987; Soons et al., 1989).  In 9 subjects, the AUC 
of oral racemic nitrendipine (20 mg) was in-
creased by 150 mL of GFJ (mean increase 106%; 
interval 64–158%).  Comparable results were ob-
tained for the Cmax and both parameters of (S)- 
and (R)-nitrendipine.  There were highly signifi-
cant differences in the AUC and Cmax between 
enantiomers.  There were no consistent effects on 
blood pressure with GFJ, and GFJ did not affect 
hemodynamic parameters (Soons et al., 1991).
 
Nondihydropyridines
 
Diltiazem
Diltiazem is a benzothiazepine calcium channel 
antagonist.  The oral bioavailability of diltiazem 
is approximately 40 to 50% due to extensive 
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presystemic metabolism (Buckley et al., 1990). 
Consumption of a single dose of diltiazem (120 
mg) with GFJ (200 mL) followed by repeated 
GFJ administration (at 0, 2, 4, 8 and 12 h) did not 
alter the AUC or Cmax of diltiazem.  No statisti-
cally significant differences were found between 
the GFJ treatment and the control values of the 
mean arterial pressure, heart rate, and PR-interval 
(Sigusch et al., 1994).  In another report, GFJ in-
take resulted in a statistically significant average 
individual increase in AUC of 20% compared 
with water.  The average individual increase in 
Cmax of diltiazem after GFJ administration was 
22%.  However, there were no statistically signifi-
cant differences in blood pressure and heart rate 
between the 2 treatments in healthy volunteers 
(Christensen et al., 2002).
Verapamil
Verapamil is used therapeutically as a race-
mate.  The systemic bioavailability of verapamil 
is only about 20% because of its extensive first-
pass extraction (McTavish and Sorkin, 1989).  In 
9 healthy volunteers, GFJ significantly increased 
AUC of S-verapamil by 36% during 12 h dose in-
terval, and increased that of R-verapamil by 28% 
in steady state.  There were no significant differ-
ences in the pharmacodynamic parameters, blood 
pressure, heart rate and PR-interval (Ho et al., 
2000).  GFJ significantly increased the AUC of 
(R, S)-verapamil at steady state by a mean of 45% 
and Cmax at steady state by 63% in 24 volunteers. 
Prolongation of PR intervals by GFJ coadmin-
istration was borderline significant; an increase 
above 350 msec occurred in 2 individuals during 
the GFJ period (Fuhr et al., 2002).  Fuhr et al. 
(2002) concluded that patients on verapamil treat-
ment should abstain from GFJ.
This short review summarizes recent data about 
the interaction between GFJ and calcium channel 
antagonists.  The extent of interaction between 
calcium channel antagonists and GFJ varies wide-
ly among drugs.  It is necessary to withhold GFJ 
for at least 3 days prior to administration of the 
drugs to prevent GFJ-drug interaction.  Although 
the AUC and Cmax of azelnidipine, efonidipine, 
felodipine, manidipine, nicardipine, nifedipine, ni-
soldipine, nitrendipine and verapamil are elevated 
by GFJ intake, both pharmacokinetic parameters 
of amlodipine and diltiazem are not affected by 
GFJ.  It is advisable to avoid combination, espe-
cially with the more affected agents, azelnidipine, 
felodipine, manidipine, nisoldipine and nitren-
dipine.  Among dihydropyridines, amlodipine 
could be an alternative drug with diltiazem as the 
alternative in the non dihydropyridine class.  It is 
important that awareness of food-drug interac-
tions increases, and actions must be taken to avoid 
undesired and harmful clinical events.
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